Abstract
Pulmonology deals with treatment of respiratory diseases, which is a challenging task with rising incidence and limitations of currently available treatments. Application of nanobiotechnology to pulmonology, nanopulmonology, offers NP-based drug and gene delivery for treatment of lung diseases as well as a route for delivery of systemic therapy. Delivery of exogenous genes to the airway epithelium in vivo has been limited by several physiological barriers, resulting in the low success rate of these systems. NP-based drug delivery systems have revolutionized the field of pharmacotherapy by presenting the ability to alter the pharmacokinetics of the conventional drugs to extend the drug retention time, reduce the toxicity, and increase the half-life of the drugs (Swai et al. 2009).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Brzoska M, Langer K, Coester C, et al. Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem Biophys Res Commun 2004;318:562–70.
Dobson J. Magnetic nanoparticles-based gene delivery. Gene Ther 2006;13:283–7.
Fink TL, Klepcyk PJ, Oette SM, et al. Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Ther 2006;13:1048–51.
Griesenbach U, Geddes DM, Alton EW. Advances in cystic fibrosis gene therapy. Curr Opin Pulm Med 2004;10:542–6.
Karathanasis E, Bhavane E, Annapragada AV. Glucose-sensing pulmonary delivery of human insulin to the systemic circulation of rats. Int J Nanomedicine 2007;2:501–13.
LiPuma JJ, Rathinavelu S, Foster BK, et al. In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species. Antimicrob Agents Chemother 2009;53:249–55.
Mohammadi Z, Dorkoosh FA, Hosseinkhani S, et al. In vivo transfection study of chitosan-DNA-FAP-B nanoparticles as a new non viral vector for gene delivery to the lung. Int J Pharm 2011;421:183–8.
Padegimas L, Kowalczyk TH, Adams S, et al. Optimization of hCFTR lung expression in mice using DNA nanoparticles. Mol Ther 2012;20:63–72.
Rogueda P, Traini D. The nanoscale in pulmonary delivery: parts I and II. Expert Opin Drug Deliv 2007;4:595–620.
Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv 2008;5:629–39.
Swai H, Semete B, Kalombo L, et al. Nanomedicine for respiratory diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1:255–63.
Sweeney LG, Wang Z, Loebenberg R, et al. Spray-freeze-dried lipociproflaxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005;305:180–5.
Vij N. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential. Expert Opin Drug Deliv 2011;8:1105–9.
Xenariou S, Griesenbach U, Ferrari S. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther 2006;13:1445–52.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Jain, K.K. (2012). Nanopulmonology. In: The Handbook of Nanomedicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-983-9_11
Download citation
DOI: https://doi.org/10.1007/978-1-61779-983-9_11
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-982-2
Online ISBN: 978-1-61779-983-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)